TABLE 1

TY027 acts as an NK₁ antagonist in vivo: effects on SP-induced flinching

Treatment	N	Mean Number of Flinches in 5 Min (± S.E.M.)
S^{^a}-10% DMSO-SP	5	37.6 (± 7.9)
S^{^a}-TY027₃₀-SP	6	10.6 (± 3.4)^*
NLX^{^b}- 10% DMSO-SP	6	26.3 (± 5.5)
NLX^{^b}-TY027₃₀-SP	6	8.0 (± 3.0)**

↵^a S, 0.9% saline (1 ml/kg s.c.) given 25 minutes before SP (10 µl, 1 mM i.t.), 10% DMSO, or TY027 (dose given in subscript = micrograms in 5 μl i.t.) 15 minutes prior to SP.
↵^b NLX (2 mg/kg s.c.) given 25 minutes before SP (10 µl, 1 mM i.t.), 10% DMSO, or TY027 (dose given in subscript = micrograms in 5 μl i.t.) 15 minutes prior to SP.
↵* P ≤ 0.05 and **P ≤ 0.01, determined using one-way ANOVA (FlashCalc) with Newman-Kuels post-hoc analysis.